High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Study Drugs:

Busulfan and melphalan are designed to bind to the DNA (genetic material) of cells, which may
cause cancer cells to die. They are commonly used in stem cell transplantation.

Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells
to die. It may help to increase the effect of busulfan and melphalan on cancer cells by not
allowing these cells to repair the DNA damage caused by busulfan or melphalan.

Busulfan Test Dose:

You will receive a test dose of busulfan by vein over about 60 minutes. This low-level test
dose of busulfan is to check how the level of busulfan in your blood levels changes over
time. This information will be used to decide the next dose needed to reach the target blood
level that matches your body size. You will most likely receive this as an outpatient during
the week before you are admitted to the hospital. If it cannot be given as an outpatient, you
will be admitted to the hospital on Day -11 (11 days before your stem cells are returned to
your body) and the test dose will be given on Day -10.

About 11 samples of blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (PK)
testing. PK testing measures the amount of study drug in the body at different time points
and will help the study doctor determine what your dose of busulfan should be on study. These
blood samples will be drawn at various timepoints before you receive busulfan and over about
the next 11 hours. The blood samples will be repeated again on the first day of high-dose
busulfan treatment Day -8. A temporary heparin lock line will be placed in your vein to lower
the number of needle sticks needed for these draws. If it is not possible for the PK tests to
be performed, you will receive the standard dose of busulfan.

If you receive the busulfan test dose as an outpatient:

On Days -12 (12 days before your stem cells are returned to your body) through Day -10, you
will receive palifermin by vein over about 30 seconds to help decrease the risk of side
effects in the mouth and throat.

You will be admitted on Day -9 and will receive fluids by vein to hydrate you. You will swish
the liquids caphosol and glutamine in your mouth 4 times a day, for about 2 minutes each
time. You will swish these liquids every day until you leave the hospital. These drugs are
also used to help decrease the risk of side effects in the mouth and throat.

On Days -8 through -5, you will receive busulfan by vein over about 3 hours.

On Days -8 and -3, you will receive gemcitabine by vein over about 3 hours.

On Day -4, you will not receive any drugs.

If you receive the busulfan test dose as an inpatient:

On Days -13 through Day -11, you will receive palifermin by vein over about 30 seconds each
day to help decrease the risk of side effects in the mouth and throat.

You will be admitted on Day -11 and will receive fluids by vein to hydrate you. You will
swish the liquids caphosol and glutamine in your mouth 4 times a day, for about 2 minutes
each time. You will swish these liquids every day until you leave the hospital. These drugs
are also used to help decrease the risk of side effects in the mouth and throat.

On Day -10, you will receive the busulfan test dose by vein over 45 minutes.

On Day -9, you will not receive any drugs.

On Days -8 and -3, you will receive gemcitabine by vein over about 3 hours on both days.

On Days -8 through -5, you will receive busulfan by vein over about 3 hours each day.

Study Drug Administration (for all patients):

On Days -9 through -2, you will receive dexamethasone by vein over about 15 minutes to help
decrease the risk of the possible side effects of the study drugs.

On Days -3 and -2, you will receive melphalan by vein over about 30 minutes on both days.

On Day -1, you will not receive any drugs.

On Day 0, your stem cells will be returned to your body by vein over 30-60 minutes.

On Days 0 through 2, you will receive palifermin by vein over about 30 seconds each day.

Beginning on Day 5, you will receive filgrastim (a drug that helps with the growth of white
blood cells) through a needle under your skin 1 time each day until your blood cell levels
return to normal.

Study Tests:

While you are in the hospital, you will be checked for any side effects as part of your
standard of care. Blood (about 2 teaspoons) will be drawn every day to check for side
effects.

As part of standard care, you will remain in the hospital for about 3-4 weeks after the
transplant. After you are released from the hospital, you must remain in the Houston area to
be monitored for infections and other transplant side effects until about Day 30. During this
time, you will return to the clinic 1 time each week and the following tests and procedures
will be performed:

- You will be asked about how you are feeling and about any side effects you may be
having.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- You will have a lung function test about 30-100 days after the transplant.

Length of Study:

You will be followed as part as the study for at least 2 years. You may be taken off study
early if the disease gets worse or you experience any intolerable side effects.

At each follow-up visit the following tests and procedures will be performed:

- Your medical history will be recorded.

- You will have a physical exam.

- Blood (about 2 teaspoons) and urine will be collected for routine tests.

- If your doctor thinks it is needed, you will have a bone marrow biopsy to check the
status of the disease.

- Bone survey: Only once a year.

You must talk to the study doctor if you want to leave the study early. It may be
life-threatening to leave the study after you have begun to receive the study drugs but
before you receive the stem cells.

This is an investigational study. Busulfan, gemcitabine, and melphalan are all FDA approved
and commercially available for the treatment of lymphoma, myeloma, and several other tumors.
The use of these study drugs together and the use of gemcitabine at the dose level used in
this study is investigational.

Up to 75 patients will take part in this study. All will be enrolled at MD Anderson.

Inclusion Criteria:

1. Age 18 to 70 years.

2. Patients with myeloma treated with first-line therapy including lenalidomide,
bortezomib or thalidomide, and one or more of the following: 2.1) M paraprotein
greater than 1 g/dL at HDC. 2.2) Less than partial response to first-line therapy.
2.3) Relapse after first-line therapy. 2.4) Relapse after a prior autologous stem-cell
transplant.

3. Adequate renal function, as defined by serum creatinine serum creatinine clearance >/=50 ml/min

4. Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase
(SGOT) and/or serum glutamate pyruvate transaminase (SGPT) normal; serum bilirubin and alkaline phosphatase proven to be due to disease involvement.

5. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced
vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) >/=50%
of expected corrected for hemoglobin and/or volume.

6. Adequate cardiac function with left ventricular ejection fraction >/=40%. No
uncontrolled arrhythmias or symptomatic cardiac disease.

7. Zubrod performance status <2.

8. Negative Beta human chorionic gonadotropin (HCG) text in a woman with child-bearing
potential, defined as not post-menopausal for 12 months or no previous surgical
sterilization

Exclusion Criteria:

1. Patients with grade >/= 3 non-hematologic toxicity from previous therapy that has not
resolved to
2. Patients with prior whole brain irradiation

3. Patients with active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA
>/=10,000 copies/mL, or >/= 2,000 IU/mL).

4. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
hepatitis C or positive hepatitis C serology.

5. Active infection requiring parenteral antibiotics.

6. HIV infection, unless the patient is receiving effective antiretroviral therapy with
undetectable viral load and normal cluster of differentiation 4 (CD4) counts

7. Patients having received radiation therapy to head and neck (excluding eyes), and
internal organs of chest, abdomen or pelvis in the month prior to enrollment.